scholarly journals Prognosis in primary mucinous ovarian carcinoma: focusing on the five pathological findings indicating metastatic mucinous carcinoma to the ovary

2022 ◽  
Vol 33 ◽  
Author(s):  
Sang won Lee ◽  
Jung-A Sung ◽  
Minsun Jung ◽  
Haeryoung Kim ◽  
Cheol Lee
Keyword(s):  
Ovarian Carcinoma ◽  
Mucinous Carcinoma ◽  
Pathological Findings ◽  
Mucinous Ovarian Carcinoma

Comprehensive Clinicopathologic and Updated Immunohistochemical Characterization of Primary Ovarian Mucinous Carcinoma

2018 ◽  
Vol 26 (4) ◽  
pp. 306-317 ◽  
Author(s):  
Dina Bassiouny ◽  
Nadia Ismiil ◽  
Valerie Dubé ◽  
Guangming Han ◽  
Matthew Cesari ◽  
...  
Keyword(s):  
Ovarian Carcinoma ◽  
Advanced Disease ◽  
Mucinous Carcinoma ◽  
Therapeutic Options ◽  
Clinicopathologic Features ◽  
Napsin A ◽  
Mucinous Ovarian Carcinoma ◽  
Mmr Proteins ◽  
Her2 Positivity

The distinction of primary mucinous ovarian carcinoma (PMOC) from other primaries or secondaries is essential for selecting therapeutic options and prognostication. We aimed to characterize the immunohistochemical profile of 36 PMOCs using an extended immunohistochemical panel, with clinicopathologic features and outcome. PAX8 was negative in 30 (83.3%), and SATB2 was negative in 32/35. HNF1B, AMACR, and napsin-A were detected in 33 (91.7%), 35 (97.2%), and 0 (0%), respectively. MMR proteins and ARID1A were retained in 100%; PTEN was lost in 4 (11.1%). P53 was aberrant in 10 (27.8%); none overexpressed p16. HER2 was positive in 6/35 (17.1%). Most PMOCs had a favorable outcome. However, recurrence is usually fatal. The typical tumor profile was CK7+, CK20+/−, CDX2+/−, PAX8−, ER−, PgR−, and SATB2−. HER2 positivity suggests a possible target for therapy in advanced disease.

scholarly journals Immunohistochemical Biomarkers as a Surrogate of Molecular Analysis in Ovarian Carcinomas: A Review of the Literature

Diagnostics ◽  
2021 ◽  
Vol 11 (2) ◽  
pp. 199 ◽  
Author(s):  
Giacomo Santandrea ◽  
Simonetta Piana ◽  
Riccardo Valli ◽  
Magda Zanelli ◽  
Elisa Gasparini ◽  
...  
Keyword(s):  
Ovarian Carcinoma ◽  
Molecular Analysis ◽  
Immunohistochemical Analysis ◽  
Cost Effective ◽  
Mucinous Carcinoma ◽  
Serous Carcinoma ◽  
Malignant Neoplasms ◽  
Low Grade ◽  
Ovarian Carcinomas ◽  
Novel Target

The term “ovarian carcinoma” encompasses at least five different malignant neoplasms: high-grade serous carcinoma, low-grade serous carcinoma, endometrioid carcinoma, mucinous carcinoma, and clear cell carcinoma. These five histotypes demonstrated distinctive histological, molecular, and clinical features. The rise of novel target therapies and of a tailored oncological approach has demanded an integrated multidisciplinary approach in the setting of ovarian carcinoma. The need to implement a molecular-based classification in the worldwide diagnostic and therapeutic setting of ovarian cancer demanded a search for easy-to-use and cost-effective molecular-surrogate biomarkers, relying particularly on immunohistochemical analysis. The present review focuses on the role of immunohistochemistry as a surrogate of molecular analysis in the everyday diagnostic approach to ovarian carcinomas.

Safety of fertility sparing management in invasive mucinous ovarian carcinoma

2021 ◽  
Vol 162 ◽  
pp. S269-S270
Author(s):  
Rachel Soyoun Kim ◽  
Ainhoa Madariaga ◽  
Liat Hogen ◽  
Danielle Vicus ◽  
Allan Covens ◽  
...  
Keyword(s):  
Ovarian Carcinoma ◽  
Fertility Sparing ◽  
Mucinous Ovarian Carcinoma

scholarly journals High frequency of BRAF mutations in primary mucinous ovarian carcinoma of Taiwanese patients

2021 ◽  
Vol 60 (6) ◽  
pp. 1072-1077
Author(s):  
Wan-Ru Chao ◽  
Yi-Ju Lee ◽  
Ming-Yung Lee ◽  
Gwo-Tarng Sheu ◽  
Chih-Ping Han
Keyword(s):  
Ovarian Carcinoma ◽  
High Frequency ◽  
Braf Mutations ◽  
Mucinous Ovarian Carcinoma

Adjuvant chemotherapy is not associated with a survival benefit for patients with early stage mucinous ovarian carcinoma

2019 ◽  
Vol 154 (2) ◽  
pp. 302-307 ◽  
Author(s):  
Dimitrios Nasioudis ◽  
Ashley F. Haggerty ◽  
Robert L. Giuntoli ◽  
Robert A. Burger ◽  
Mark A. Morgan ◽  
...  
Keyword(s):  
Adjuvant Chemotherapy ◽  
Ovarian Carcinoma ◽  
Survival Benefit ◽  
Early Stage ◽  
Mucinous Ovarian Carcinoma

Abstract 3283: GWAS identifies risk variants for mucinous ovarian carcinoma

2014 ◽  
Author(s):  
Linda E. Kelemen ◽  
Jonathan Tyrer ◽  
Catherine M. Phelan ◽  
Susan J. Ramus ◽  
Andrew Berchuck ◽  
...  
Keyword(s):  
Ovarian Carcinoma ◽  
Risk Variants ◽  
Mucinous Ovarian Carcinoma

Comprehensive genomic profiling of mucinous ovarian carcinoma with comparisons to mucinous colorectal carcinoma

2019 ◽  
Vol 154 ◽  
pp. 63
Author(s):  
N.L. Jones ◽  
D. Arguello ◽  
R.W. Holloway ◽  
T.J. Herzog ◽  
A.C. ElNaggar ◽  
...  
Keyword(s):  
Colorectal Carcinoma ◽  
Ovarian Carcinoma ◽  
Genomic Profiling ◽  
Comprehensive Genomic Profiling ◽  
Mucinous Ovarian Carcinoma

scholarly journals Mucinous ovarian carcinoma: Slippery business

Cancer ◽  
2010 ◽  
Vol 117 (3) ◽  
pp. 451-453 ◽  
Author(s):  
Robert A. Soslow
Keyword(s):  
Ovarian Carcinoma ◽  
Mucinous Ovarian Carcinoma

scholarly journals Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors

2015 ◽  
Vol 7 (1) ◽  
Author(s):  
Georgina L. Ryland ◽  
◽  
Sally M. Hunter ◽  
Maria A. Doyle ◽  
Franco Caramia ◽  
...  
Keyword(s):  
Ovarian Carcinoma ◽  
Mutational Landscape ◽  
Mucinous Ovarian Carcinoma

scholarly journals Ovarian metastases of pancreatic adenocarcinoma: clinical presentation, role of surgery, and potential value of the mutational profile for the differential diagnosis with primary mucinous ovarian carcinoma

2021 ◽  
Vol 13 ◽  
pp. 175883592110534
Author(s):  
Alice de Malet ◽  
Magali Svrcek ◽  
Anne Kerbaol ◽  
Nathalie Theou-Anton ◽  
Sandra Granier ◽  
...  
Keyword(s):  
Pancreatic Adenocarcinoma ◽  
Surgical Resection ◽  
Mucinous Carcinoma ◽  
Significant Morbidity ◽  
Ovarian Metastases ◽  
Histological Data ◽  
Next Generation Sequencing Ngs ◽  
Mucinous Ovarian Carcinoma ◽  
Pancreatic Origin

Background: Ovarian metastases (OM) of pancreatic adenocarcinoma (PA) (OM-PA) can mimic primary ovarian mucinous carcinoma (POMC) on imaging and histology. These metastases are often symptomatic and not highly chemosensitive, so that oophorectomy may be considered. Aims: The aims of this study were to compare the characteristics of OM-PA and POMC, and discuss the role of surgery. Patients and Methods: Clinical, imaging, and histological data of patients with OM-PA and POMC (2000–2017) in three tertiary centers were reviewed. Twenty-six genes were analyzed by next generation sequencing (NGS) on both primary PA and OM-PA. Results: Twenty-two women with OM-PA ( n = 13, 11 with surgical resection) or POMC ( n = 9) were selected. OM-PA were smaller than POMC ( p = 0.02); imaging, histological, and immunohistochemistry data did not clearly differentiate OM-PA from POMC in 12 of 22 cases (54%). Seven PA/OM-PA pairs were analyzed, and a concordant KRAS mutation was identified in all cases. In four OM-PA, concordant mutations were also found in TP53 ( n = 3), SMAD4 ( n = 1), MET ( n = 1), and PDGFRA ( n = 1) genes. The aim of oophorectomy in 11 OM-PA was for antalgic ( n = 6) or curative ( n = 5) intent. Pain improved in 4/6 of the former patients, but 2/6 had significant morbidity, and 2/6 died of rapid tumor progression. After oophorectomy, median progression-free and overall survivals were 6 (0–11) and 8 months (1–131), respectively. Conclusion: Analysis of mutation profiles in both primary PA and ovarian tumors, especially KRAS, can help to determine the pancreatic origin of OM-PA. Surgical resection of OM-AP in highly selected patients may improve pelvic symptoms but may also cause significant morbidity. The benefit to survival requires further studies.

Sign in / Sign up

Export Citation Format

Share Document